Singer AW, et al. - This retrospective cohort study analyzed the correlation between direct-acting antiviral (DAA) exposure in the treatment of hepatitis C virus infection with the risk of incident liver cancer in real-world data using the United States administrative claims data through March 31, 2017. During this research adult HCV patients exposed to DAAs were compared with contemporary adult HCV patients without evidence of HCV treatment and historical HCV patients treated with interferon prior to the introduction of DAAs. Findings displayed that relative to untreated HCV patients, DAA-treated patients were older, more likely to be male, with a greater tendency of having cirrhosis at baseline. A link was illustrated between DAA-based treatment with a reduced risk of incident liver cancer relative to both no HCV treatment and to interferon-based treatment in the pre-DAA era.